MAR-FINGOLIMOD CAPSULE

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)

Disponible desde:

MARCAN PHARMACEUTICALS INC

Código ATC:

L04AA27

Designación común internacional (DCI):

FINGOLIMOD

Dosis:

0.5MG

formulario farmacéutico:

CAPSULE

Composición:

FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG

Vía de administración:

ORAL

Unidades en paquete:

28

tipo de receta:

Prescription

Área terapéutica:

Immunomodulatory Agents

Resumen del producto:

Active ingredient group (AIG) number: 0152886001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2019-03-11

Ficha técnica

Page 1 of 64
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MAR-FINGOLIMOD
Fingolimod capsules
Capsules, 0.5 mg fingolimod (as fingolimod hydrochloride), Oral
Manufacturer’s Standard
Sphingosine 1-phosphate receptor modulator
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112
Ottawa, ON, K2E 1A2
Date of Initial Authorization:
MAR 11, 2019
Date of Revision:
MAR 03, 2022
Submission Control Number: 257291
Page 2 of 64
RECENT MAJOR LABEL CHANGES
2 Contraindications
03/2022
4 Dosage and Administration
03/ 2022
7 Warnings and Precautions
03/ 2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES……………………………………………………………………………………………….2
TABLE OF
CONTENTS…………………………………………………………………………………………………………………2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
......................................................................................................................
4
1.2
Geriatrics
.......................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 7
4.4
Administration
....................................................................